- Home
- GLPG
GLPG
Galapagos NV
as 07-30-2025 2:36pm EST
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
| Founded: | 1999 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.0B | IPO Year: | 2005 |
| Target Price: | $25.33 | AVG Volume (30 days): | 327.4K |
| Analyst Decision: | Sell | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.36 - $33.86 | Next Earning Date: | 07-23-2025 |
| Revenue: | $323,674,692 | Revenue Growth: | 5.43% |
| Revenue Growth (this year): | 0.78% | Revenue Growth (next year): | -1.28% |
Latest Galapagos NV News
GLPG Breaking Stock News: Dive into GLPG Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Galapagos Appoints Aaron Cox as Chief Financial Officer
GlobeNewswire
a month ago
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Simply Wall St.
a month ago
Owning 37% shares,institutional owners seem interested in Galapagos NV (AMS:GLPG),
MT Newswires
2 months ago
Galapagos Reports Positive Safety Data for GLPG5101 in Lymphoma Trial
GlobeNewswire
2 months ago
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
GlobeNewswire
2 months ago
Galapagos Creates New Subscription Right Plan
GlobeNewswire
3 months ago
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
GlobeNewswire
3 months ago
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
Compare GLPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLPG Galapagos NV - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.